Tarcocimab and KSI-501 in wet AMD: DAYBREAK study explores in a definitive manner immediacy through the loading phase and real-world durability and, in the case of KSI-501, the potential for better efficacy DAYBREAK study design: a registrational study for both tarcocimab and KSI-501 DAYBREAK uses an AI-based tool to precisely measure fluid in the eye so that treatment is optimized for each patient • In high need patients, treats until dry, enables monthly dosing and detects disease reactivations earlier. • In long durability patients , allows patients without active disease to safely to 6-month dosing. Quadrant of core unmet need We are expecting to close screenings for DAYBREAK by the end of August 30